Topical 0.5% ganciclovir therapy for cytomegalovirus corneal endothelitis and iritis

Topical 0.5% ganciclovir therapy for cytomegalovirus corneal endothelitis and iritis - 0.5%ganciclovir therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018977

Enrollment

Registered

2015-09-10

Start date

2015-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cytomegalovirus corneal endotheliitis and iritis

Interventions

eye drop 8times for severe case 6times for modarete case 4times for mild case 1drop per 1time taper after improvement stop when PCR shows negative of CMV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diagnosed as cytomegalovirus corneal endotheliitis and iritis over16

Exclusion criteria

Exclusion criteria: inappropriate person allergy for ganciclovir pregnant woman

Design outcomes

Primary

Measure	Time frame
rate of improvement of inflammation (disappear of inflammation and more than 500 endothelial cell)	—

Countries

Japan

Contacts

Public ContactKatsue Imamachi

Shimane university hospital Ophthalmol

kimama@med.shimane-u.ac.jp0853-20-2284

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026